Information Provided By: 
Fly News Breaks for January 25, 2019
APTO
Jan 25, 2019 | 07:44 EDT
As previously reported, Oppenheimer analyst Matthew Biegler initiated Aptose Biosciences with an Outperform rating and $6 price target, citing the commercial potential of CG-806 in two major hematology/oncology indications. In a research note to investors, Biegler says he believes CG-806 can selectively disable key signaling pathways that cancer cells need without the "safety baggage" usually associated with multi-kinase inhibitors. Biegler says he would be a buyer of Aptose ahead of CG-806's expected 1H19 entry into the clinic.
News For APTO From the Last 2 Days
There are no results for your query APTO
